patent.fyi
Applications  /  US 2026/0355289
United States Patent Application Publication

US 2026/0355289 A1

Published
Nov 12, 2026
Filed
May 19, 2026
Earliest date on the face
May 14, 2019
Classification
A61K 38/36
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Fibrinogen substrate replacement

What ifWhat if intravenous fibrinogen supplied the material needed to build a fibrin network?
Claim language“the A2 domain”

A fibrinogen concentrate replenishes circulating fibrinogen when its level is low. Thrombin cleaves the infused fibrinogen, and the resulting fibrin monomers assemble into fibers.

1.1Fibrin cross-linking enzyme replacement

What ifWhat if factor XIII replacement stabilized the fibrin network in an individual with factor XIII deficiency?
Claim language“the A2 domain”

Intravenous factor XIII concentrate restores the protein available for activation by thrombin in the presence of calcium. Activated factor XIII forms covalent links between fibrin chains and anchors alpha-2-antiplasmin to fibrin, increasing the network's resistance to breakdown.

1.1Local fibrin sealant application

What ifWhat if a two-component fibrin sealant formed a network directly on a bleeding tissue surface?
Claim language“the A2 domain”

A dual-barrel applicator combines a concentrated fibrinogen solution and a thrombin solution at the tissue surface. Thrombin converts fibrinogen to fibrin, forming an adherent network over the bleeding site.

1.2Clot stabilization after dental extraction

What ifWhat if the individual had an extraction socket at risk of recurrent bleeding while taking an oral anticoagulant?
Claim language“has rheumatoid arthritis”

Tranexamic acid solution irrigates the socket or wets gauze held against it. Local inhibition of plasminogen binding slows the breakdown of the socket's fibrin clot.

1.2Clot support during postpartum hemorrhage

What ifWhat if the individual had postpartum hemorrhage with a low plasma fibrinogen concentration?
Claim language“has rheumatoid arthritis”

A plasma fibrinogen assay identifies a shortage of substrate for clot formation. Intravenous fibrinogen concentrate or cryoprecipitate supplies fibrinogen for thrombin to convert into fibrin at bleeding sites.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Fibrin treatment in veterinary wound models

A veterinary wound dressing test uses plasma from canine donors to form fibrin clots on porous dressing coupons. Paired coupons receive either an A2 domain solution or its carrier buffer after clot formation. Following a plasmin challenge, a balance records the wet clot mass remaining on each coupon after a fixed drain interval.

Component substitution

Tranexamic acid in place of A2

Tranexamic acid replaces the A2 domain as the active component in an aqueous formulation. The formulation is added to a preformed fibrin clot before exposure to plasminogen and tissue plasminogen activator. Tranexamic acid occupies lysine-binding sites on plasminogen and reduces its recruitment to fibrin, slowing clot breakdown.

Parameter or scale variation

Staggered exposure of preformed fibrin clots

A microplate holds 100 microliters of citrated plasma from a donor with rheumatoid arthritis in each well, with thrombin and calcium added to form clots. Equal aliquots of A2 domain solution are added to separate groups 5, 20, and 40 minutes after clot initiation. Each group has a carrier-only control and receives the same fibrinolytic challenge 10 minutes after treatment. A plate reader measures the time from challenge to a 50 percent decrease in clot-associated turbidity.

Combination with existing systems

Fibrin treatment in an arthroscopic scaffold

A dual-syringe arthroscopic applicator carries fibrinogen mixed with the A2 domain in one barrel and thrombin with calcium in the other. A mixing tip combines the streams as the applicator deposits them onto a prepared joint surface. Thrombin converts fibrinogen into a local scaffold, placing the A2 domain in contact with the fibrin as it forms.

Fibrin treatment in a perfusion chamber

A parallel-plate flow chamber holds a preformed fibrin layer on a removable coverslip. A syringe pump moves A2 domain solution across the layer, followed by a buffer rinse and a fibrinolytic challenge. A fluorescence microscope tracks loss of labeled fibrin over time in paired chambers receiving A2 domain solution or carrier buffer.

Automated or data-driven variant

Automated screening of fibrin treatment response

A liquid handler dispenses plasma from a donor with rheumatoid arthritis into a microplate and forms matched fibrin clots. It adds a dilution series of the A2 domain to treatment wells and adds carrier buffer to control wells. After a common fibrinolytic challenge, a plate reader records turbidity over time, and software ranks the concentrations by the change in clot half-lysis time relative to the matched controls.

Specific version of a part

Intravenous recombinant A2 domain

A recombinant expression system produces the isolated A2 domain, and chromatography purifies the soluble protein. A sterile buffered solution delivers the purified domain by intravenous infusion.

Local A2 domain delivery

A sterile buffered solution carries purified A2 domain to a fibrin-containing wound bed through a blunt applicator. The liquid spreads over the exposed clot and brings the domain into contact with fibrin fibers.

Seropositive rheumatoid arthritis setting

The individual has persistent inflammatory synovitis and circulating antibodies against cyclic citrullinated peptides. A plasma clot-lysis assay measures fibrinolysis separately from the clinical and serologic findings.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0118161 A1
Published
May 7, 2009
Filed
Oct 18, 2007
Class
A61K 38/17
Document BUS 2016/0109442 A1
Published
Apr 21, 2016
Filed
Jun 14, 2011
Class
G01N 33/564
Claim 1
Document A
Document B
1.1the step of delivering to the individual an effective amount of the A2 domain of von Willebrand factor or a functional derivative or fragment thereof
In one embodiment of the invention, there is a method of treating and/or preventing sepsis in an individual, comprising delivering to the individual a therapeutically effective amount of an A2 domain of von Willebrand factor, or a fragment of said A2 domain.
A · US 2009/0118161 A1 · ¶ 19
1.2wherein the individual has rheumatoid arthritis.
The present inventor has investigated the presence of talin in the plasma or the serum of a patient with rheumatoid arthritis.
B · US 2016/0109442 A1 · ¶ 11

An empty cell means only that no passage was reproduced there.

Statements in these documents
The invention is directed to methods to treat, diagnose and/or prevent medical conditions, such as sepsis or thrombosis, utilizing aspects of the A2 domain of von Willebrand factor.
A · US 2009/0118161 A1 · ¶ 3
It is a common diagnosis among critically ill patients and carries a high mortality rate.
A · US 2009/0118161 A1 · ¶ 4
However, in previous reports, the sensitivity of the rheumatoid factor is 75 to 80%, the specificity thereof is 50 to 70%, and the sensitivity of the anti-CCP antibody is 50 to 75%, and the specificity is 85 to 95%, which are not necessarily satisfactory (see Non-Patent Literatures 2 and 3).
B · US 2016/0109442 A1 · ¶ 4
The present invention aims to provide a test method for rheumatoid arthritis and a kit for rheumatoid arthritis test by searching novel markers that have not been previously known and being based on the found novel markers in the searching.
B · US 2016/0109442 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355289 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355289/, SHA-256 90699d62c8040c74e433665cc6398af9c39b032ffb017d9e08f85b1937969bc5
First published
Permanent addresshttps://patent.fyi/US20260355289/
Content fingerprint (SHA-256)90699d62c8040c74e433665cc6398af9c39b032ffb017d9e08f85b1937969bc5
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi